Education
About Us
Working with TipRanks
Follow Us
Celldex Therapeutics Inc (CLDX)
NASDAQ:CLDX
Top Page
Celldex
(NASDAQ:CLDX)
43Neutral
Positive Factors
Clinical Trials
Barzolvolimab holds the most compelling clinical profile to date across two large Phase 2 urticaria studies and is meaningfully ahead of competitors with enrollment well underway in Phase 3 trials.
Financial Position
The company ended the year financially strong with $725.3 million in cash, which management believes should fund all ongoing operations through 2027.
Negative Factors
Competitive Landscape
CDX-622 exhibited similar potency to parental antibodies tezepelumab and barzolvolimab.
Celldex (CLDX) vs. S&P 500 (SPY)
Market Cap
$1.41B
Dividend YieldN/A
Average Volume (3M)780.59K
Price to Earnings (P/E)―
Beta (1Y)1.16
Revenue Growth1.99%
EPS Growth15.95%
CountryUS
Employees160
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.44
Shares Outstanding66,383,810
10 Day Avg. Volume870,058
30 Day Avg. Volume780,590
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)200.19
Price to Cash Flow (P/CF)-10.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$65.38Price Target Upside224.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Celldex Business Overview & Revenue Model
Company DescriptionCelldex Therapeutics, Inc. engages in the research, development, and commercialization of immunotherapies and other targeted biologics. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.
How the Company Makes MoneyCelldex makes money primarily through the development and commercialization of its proprietary drug candidates. Revenue streams include upfront and milestone payments from strategic collaborations and partnerships with other pharmaceutical companies, as well as potential royalties from successfully marketed products resulting from these partnerships. Additionally, the company may generate income from government grants and research funding aimed at supporting its innovative therapeutic programs. As Celldex advances its drug candidates through clinical trials and obtains regulatory approvals, it aims to generate revenue from product sales and licensing agreements.
Celldex Financial Statement Overview
Summary
Celldex exhibits robust equity stability and low leverage, which are strong points in its financial profile. However, persistent operating losses and negative cash flows indicate significant challenges in achieving profitability. Continued investment in growth opportunities could improve long-term prospects, but current financial performance reflects the typical volatility and risk associated with the biotechnology sector.Income Statement
The company's revenue has shown some growth over the years, with a notable increase from 2022 to 2023. However, the consistent negative EBIT and net income margins highlight ongoing profitability challenges. The gross profit margin is positive, but the net income remains negative, indicating high operational costs relative to revenue.45
Neutral
Balance Sheet
Celldex has maintained a strong equity position with a high equity ratio, suggesting financial stability. The debt-to-equity ratio is low, indicating limited leverage. However, the persistent negative net income impacts the return on equity, reflecting challenges in generating shareholder value.60
Neutral
Cash Flow
The operating cash flow has been negative, indicating challenges in generating cash from core operations. Despite this, the company has managed to maintain liquidity through financing activities. Free cash flow remains negative, aligning with the company's continued investment in growth and development.50
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 7.02M | 6.88M | 2.36M | 4.65M | 7.42M | Gross Profit |
| 7.02M | 3.88M | 957.00K | 1.58M | -35.12M | EBIT |
| -195.08M | -154.54M | -115.23M | -71.24M | -63.35M | EBITDA |
| -191.90M | -139.03M | -104.20M | -66.08M | -45.64M | Net Income Common Stockholders |
| -157.86M | -141.43M | -122.78M | -70.51M | -59.78M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 725.28M | 423.60M | 304.95M | 408.25M | 194.42M | Total Assets |
| 792.34M | 465.63M | 352.74M | 444.65M | 235.84M | Total Debt |
| 3.81M | 2.54M | 4.03M | 3.04M | 3.48M | Net Debt |
| -24.54M | -32.27M | -25.40M | -36.10M | -40.35M | Total Liabilities |
| 45.34M | 36.46M | 26.53M | 25.18M | 26.48M | Stockholders Equity |
| 747.00M | 429.17M | 326.20M | 419.48M | 209.36M |
| Cash Flow | Free Cash Flow | |||
| -157.78M | -109.11M | -105.56M | -62.16M | -41.96M | Operating Cash Flow |
| -157.78M | -107.29M | -103.73M | -60.91M | -40.40M | Investing Cash Flow |
| -290.13M | -105.78M | 89.94M | -216.16M | -98.22M | Financing Cash Flow |
| 441.45M | 218.46M | 4.08M | 272.37M | 171.23M |
Celldex Technical Analysis
Negative
20.14
Price Trends
23.05
Negative
24.75
Negative
30.62
Negative
Market Momentum
-0.79
Negative
41.84
Neutral
53.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLDX, the sentiment is Negative. The current price of 20.14 is below the 20-day moving average (MA) of 21.19, below the 50-day MA of 23.05, and below the 200-day MA of 30.62, indicating a bearish trend. The MACD of -0.79 indicates Negative momentum. The RSI at 41.84 is Neutral, neither overbought nor oversold. The STOCH value of 53.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLDX.
Celldex Risk Analysis
Celldex disclosed 62 risk factors in its most recent earnings report. Celldex reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Celldex Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $143.73M | ― | -62.17% | ― | 16.68% | -295.28% | |
52 Neutral | $521.31M | ― | -137.46% | ― | -41.38% | -49.25% | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% | |
43 Neutral | $1.41B | ― | -26.84% | ― | 1.99% | 15.95% | |
42 Neutral | $249.32M | ― | -31.41% | ― | 389.82% | -22.66% | |
42 Neutral | $110.00M | ― | -54.21% | ― | -78.55% | -0.92% |
* Healthcare Sector Average
Performance Comparison
CLDX
Celldex
20.14
-22.38
-52.63%
XOMA
Xoma
20.27
-5.50
-21.34%
MGNX
MacroGenics
2.20
-13.86
-86.30%
PGEN
Precigen
1.74
0.31
21.68%
FATE
Fate Therapeutics
0.94
-6.29
-87.00%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.